natgillin/translations-raw huggingface dataset:
The CHMP decided that Aprovel’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Aproveli kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Aranesp’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Aranespi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Arava’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Arava kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Arixtra’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Arixtra kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Avandamet’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Avandameti kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda müügiloa.
The CHMP decided that Avandia’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Avandia kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Avastin’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Avastini kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Avonex’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Avonexi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Axura’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Axura kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Azilect’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Azilecti kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that BeneFIX’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et BeneFIXi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda müügiloa.
The CHMP decided that Betaferon’s benefits are greater than its risks and recommended that Betaferon be granted marketing authorisation.
Inimravimite komitee otsustas, et Betaferoni kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Bondenza’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Bondenza kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Bondronat’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Bondronati kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Bonviva’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Bonviva kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Bridion’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Bridioni kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Brilique’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et ravimi Brilique kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Brinavess’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Brinavessi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Byetta’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Byetta kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Caelyx’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Caelyxi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda müügiloa.
The CHMP decided that Cayston’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Caystoni kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda müügiloa.
The CHMP decided that CellCept’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et CellCepti kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Celsentri’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Celsentri kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Celvapan’s benefits of are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Celvapani kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda vaktsiini müügiloa.
The CHMP decided that Ceplene’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Ceplene kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Cerezyme gives effective control of the non-neurological symptoms of types 1 and 3 Gaucher disease.
Inimravimite komitee otsustas, et Cerezyme võimaldab I ja III tüüpi Gaucher’ tõve mitteneuroloogilisi sümptomeid efektiivselt leevendada.
The CHMP decided that Cervarix’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Cervarixi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda müügiloa.
The CHMP decided that Cetrotide’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Cetrotide kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda müügiloa.
The CHMP decided that Cialis’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Cialise kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Cimzia’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Cimzia kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Clopidogrel Zentiva’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Clopidogrel Zentiva kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that CoAprovel’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et CoAproveli kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Combivir’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Combiviri kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Conbriza’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Conbriza kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Copalia’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Copalia kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Crixivan’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Crixivani kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Cubicin’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Cubicini kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Cystagon’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Cystagoni kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Dacogen’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Dacogeni kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Dafiro’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Dafiro kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that DaTSCAN’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et DaTSCANi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Docetaxel Winthrop’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Docetaxel Winthropi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Doribax’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Doribaxi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that DuoTrav’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et DuoTravi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda müügiloa.
The CHMP decided that Ebixa’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Ebixa kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Effentora’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Effentora kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Efficib’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Efficibi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Efient’s benefits are greater than its risks, when given together with aspirin, for the prevention of atherothrombotic events in patients with acute coronary syndrome undergoing primary or delayed percutaneous coronary intervention.
Inimravimite komitee otsustas, et Efienti kasulikkus manustamisel koos aspiriiniga aterotrombootiliste tüsistuste ennetamiseks ägeda koronaarsündroomiga patsientidel, kellele tehakse primaarne või hiline perkutaanne koronaarangioplastika, on suurem kui ravimiga kaasnevad riskid.
The CHMP decided that ellaOne’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et ellaOne kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Elonva’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Elonva kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Emend’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Emendi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Enbrel’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Enbreli kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Epivir’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Epiviri kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Erbitux’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Erbituxi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda müügiloa.
The CHMP decided that Evicel’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Eviceli kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Exforge’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Exforge kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Exjade’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Exjade kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Extavia’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Extavia kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Fablyn’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Fablyni kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Fabrazyme’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Fabrazyme kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Fendrix’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Fendrixi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda vaktsiini müügiloa.
The CHMP decided that Ferriprox’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Ferriproxi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Fertavid’s benefits are greater than its risks and recommended that Fertavid be given marketing authorisation.
Inimravimite komitee otsustas, et Fertavidi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Firazyr’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Firazyri kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Firdapse’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Firdapse kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Focetria’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Focetria kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda vaktsiini müügiloa.
The CHMP decided that Foclivia’s benefits are greater than its risk and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Foclivia kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda vaktsiini müügiloa.
The CHMP decided that for patients with Fabry disease treatment with Replagal might provide long- term clinical benefits.
Inimravimite komitee otsustas, et ravi Replagaliga võib olla Fabry tõvega patsientidele pikaajaliselt kliiniliselt kasulik.
The CHMP decided that Fosavance’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Fosavance kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Ganfort’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Ganforti kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Gardasil’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Gardasili kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda vaktsiini müügiloa.
The CHMP decided that Glivec’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Gliveci kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Glustin’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Glustini kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that GONAL-f’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et ravimi GONAL–f kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Halaven’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Halaveni kasulikkus on suurem kui sellega kaasnevad riskid, ning soovitas anda ravimi müügiloa.
The CHMP decided that Helixate NexGen’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Helixate NexGeni kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda müügiloa.
The CHMP decided that Herceptin’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Herceptini kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Hirobriz Breezhaler’s benefits are greater than its risks and recommended that Hirobriz Breezhaler be given marketing authorisation.
Inimravimite komitee otsustas, et Hirobriz Breezhaleri kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Humira’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Humira kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Hycamtin’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Hycamtini kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Ilaris’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Ilarise kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Imprida’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Imprida kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Increlex’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Increlexi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Infanrix hexa’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Infanrix hexa kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda vaktsiini müügiloa.
The CHMP decided that Infanrix Penta’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Infanrix Penta kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda vaktsiini müügiloa.
The CHMP decided that Inovelon’s benefits are greater that its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Inoveloni kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Instanyl’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Instanyli kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Insulatard’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Insulatardi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Insuman’s benefits are greater than its risks for the treatment of type 1 and type 2 diabetes.
Inimravimite komitee otsustas, et Insumani kasulikkus I ja II tüüpi diabeedi ravis on suurem kui sellega kaasnevad riskid.
The CHMP decided that Intanza’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Intanza kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda vaktsiini müügiloa.
The CHMP decided that Intelence’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Intelence kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Intrinsa’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Intrinsa kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Invega’s benefits are greater than its risks in adults and recommended that it be given marketing authorisation for schizophrenia and schizoaffective disorder.
Inimravimite komitee otsustas, et Invega kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa skisofreenia ja skisoafektiivse häire raviks.
The CHMP decided that Invirase’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Invirase kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.